AVROBIO, Inc. (AVRO) News

AVROBIO, Inc. (AVRO): $1.85

0.11 (+6.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 450

in industry

Filter AVRO News Items

AVRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AVRO News Highlights

  • AVRO's 30 day story count now stands at 11.
  • Over the past 21 days, the trend for AVRO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about AVRO are GENE, AG and DRUG.

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now

AVROBIO, Inc. (AVRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | January 25, 2022

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks

AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | January 7, 2022

AVROBIO grants (NASDAQ:AVRO)

AVROBIO (AVRO) granted non-statutory stock options for the purchase of up to 30.5K shares to three new employees as inducement awards.The stock options were granted on Jan

Seeking Alpha | January 6, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., January 06, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 30,500 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | January 6, 2022

Mizuho Securities Sticks to Their Buy Rating for Avrobio (AVRO)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price target of $6.00. The company's shares closed last Wednesday at $2.29. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.40, which is an 115.1% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $14.00 price target. See the top stocks recommended by analysts >> The company has a one-year high of $20.07 and a one-year low of $3.17. Currently, Avrobio has an average volume of 422.5K.

Catie Powers on TipRanks | January 5, 2022

Needham Sticks to Its Buy Rating for Avrobio (AVRO)

Needham analyst Gil Blum maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price target of $8.00. The company's shares closed last Tuesday at $2.70. According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Currently, the analyst consensus on Avrobio is a Moderate Buy with an average price target of $10.50, a 218.2% upside from current levels.

Christine Brown on TipRanks | January 4, 2022

AvroBio shares plunge after company halts development of Fabry drug

Genetic disease-focused AvroBio Inc. has cut its most advanced drug in development, sending shares down by one-third on Tuesday.

Yahoo | January 4, 2022

Wedbush Says Avrobio Shares Still Undervalued Despite 33% Fall

By Sam Boughedda

Yahoo | January 4, 2022

Why Avrobio's Shares Are Plunging Today

View more earnings on AVROSee more from BenzingaPlus Therapeutics Shares Shine After Two Milestones To Manufacture Its Lead RadiotherapeuticSanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency Impact© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Yahoo | January 4, 2022

AVROBIO Reprioritizes Pipeline Programs

CAMBRIDGE, Mass., January 04, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024. The company is deprioritizing its Fabry disease program due to several factors, including new clinical data showing variable engraftment patterns from

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5493 seconds.